Related Experiment Video
Updated: Mar 18, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
Clinical validation of NGS technology for HLA: An early adopter's perspective
1UNC Hospitals, McLendon Clinical Laboratories, United States; University of North Carolina at Chapel Hill School of Medicine, Department of Pathology and Laboratory Medicine, Chapel Hill, NC 27514, United States.
Abstract:
Clinical validation of NGS for HLA typing has been a topic of interest with many laboratories investigating the merits. NGS has proven effective at reducing ambiguities and costs while providing more detailed information on HLA genes not previously sequenced. The ability of NGS to multiplex many patients within a single run presents unique challenges and sequencing new regions of HLA genes requires application of our knowledge of genetics to accurately determine HLA typing. This review represents my laboratory's experience in validation of NGS for HLA typing. It describes the obstacles faced with validation of NGS and is broken down into pre-analytic, analytic, and post-analytic challenges. Each section includes solutions to address them.

